|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.86 USD | +3.79% |
|
-0.39% | +4.19% |
Business description: MBX Biosciences, Inc.
Number of employees: 63
Sales by Activity: MBX Biosciences, Inc.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Geographical breakdown of sales: MBX Biosciences, Inc.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: MBX Biosciences, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Peter Hawryluk
CEO | Chief Executive Officer | 57 | 2019-12-31 |
Rick Bartram
DFI | Director of Finance/CFO | 45 | 2022-03-31 |
Stewart Hallett
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-31 |
Salomon Azoulay
CTO | Chief Tech/Sci/R&D Officer | 69 | 2024-05-31 |
Jim DeNike
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: MBX Biosciences, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Peter Hawryluk
CHM | Chairman | 57 | 2019-12-31 |
| Director/Board Member | 66 | 2020-06-30 | |
Patrick Heron
BRD | Director/Board Member | 55 | 2020-06-30 |
Ora Pescovitz
BRD | Director/Board Member | 69 | 2022-04-04 |
Tiba Aynechi
BRD | Director/Board Member | 51 | 2022-11-30 |
Steven Ryder
BRD | Director/Board Member | 75 | 2023-12-31 |
Steven Hoerter
CHM | Chairman | 55 | 2025-11-05 |
Laurie Stelzer
BRD | Director/Board Member | 58 | 2026-01-19 |
Company details: MBX Biosciences, Inc.
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.79% | -0.39% | +413.44% | - | 1.56B | |
| +2.05% | +2.86% | -0.81% | -9.16% | 44.74B | |
| +0.39% | +0.85% | +51.91% | +31.44% | 34.75B | |
| -0.25% | +2.44% | +35.64% | +37.95% | 29.82B | |
| -2.06% | -2.47% | +7.62% | -13.71% | 28.37B | |
| -0.55% | -2.93% | +173.97% | +369.82% | 19.07B | |
| +3.65% | +5.44% | +75.36% | +232.52% | 14.93B | |
| -3.68% | +0.63% | +65.75% | +162.66% | 14.32B | |
| -2.46% | -8.54% | +3,504.15% | +3,844.27% | 13.93B | |
| +1.00% | -0.58% | +38.07% | +3.39% | 13.17B | |
| Average | +0.19% | -0.97% | +436.51% | +517.69% | 21.47B | |
| Weighted average by Cap. | +0.07% | -0.65% | +272.00% | +318.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MBX Stock
- Company MBX Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
